STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #327 by analyst upside · 2026-08-13
IFRX
InflaRx N.V.
Healthcare · Market Cap $296M · P/E 0x
ANALYST PRICE TARGET
+292.0%
implied upside to consensus target
Current Price $2.01
Consensus Target $7.88
Bull Target $14.01
Bear Target $3.0
Analysts Covering 8
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
7
Hold
1
Sell
0
52-Week Low $0.78
52-Week High $2.95
YTD Return +84.4%
FUNDAMENTALS
Market Cap $296M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.58
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $-0M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $0.78
52-Week High $2.95
Current Price $2.01
Bear Target $3.0
Bull Target $14.01
● Now $2.01 ● Target $7.88
TRADING DATA
Avg Volume 1.2M
YTD Return +84.4%
Analyst Count 8
Consensus Buy
Upside to Target +292.0%
Last Updated 2026-08-13

ANALYST SUMMARY

InflaRx N.V. (IFRX) is currently trading at $2.01 with a Wall Street consensus price target of $7.88, implying potential upside of 292.0% over the next 12 months. 8 analysts currently cover IFRX, with a consensus rating of Buy - 88% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $14.01, while the most cautious has a target of $3.0.

IFRX operates in the Healthcare sector with a market capitalisation of $296M. The stock is up 84.4% year-to-date and is currently trading near the upper end of its 52-week range of $0.78 – $2.95.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for IFRX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Raymond James ↑ Upgrade
Outperform → Strong Buy 2026-05-13 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-05-11 31% win rate (48 calls)
Cantor Fitzgerald - Reiterated
Overweight → Overweight 2026-05-11 40% win rate (10 calls)
Guggenheim reit
Buy → Buy 2026-04-21 62% win rate (8 calls)
Guggenheim - Reiterated
Buy → Buy 2026-03-20 62% win rate (8 calls)
HC Wainwright & Co. reit
Buy → Buy 2025-12-30 31% win rate (48 calls)
Leerink Partners ↓ Downgrade
Outperform → Market Perform 2025-12-03 29% win rate (7 calls)
Guggenheim - Reiterated
Buy → Buy 2025-11-10 62% win rate (8 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
39
out of 100
Coverage depth
17/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →